GAFFI’s Chief Executive honoured as a Fellow of the American Academy of Microbiology

Posted .


Professor David Denning 2019The 2021 list of new Fellows of the American Academy of Microbiology has included Professor David Denning. The Academy, the honorific leadership group within the American Society for Microbiology, recognizes excellence, originality, service and leadership in the microbial sciences. Election to the Academy is a mark of distinction. 

Nominated by Professor Neil Gow FRS FMedSci of the University of Exeter:

“Without doubt, David Denning is one of the key opinion leaders in medical mycology whose work has proved transformational and has had widespread influence on basic science, the treatment and management of fungal disease and the availability of antifungal drugs in low-income countries. As a scientist, his work has had an enormous impact in an extremely widely of a range of topics including fungal biology, pathogenesis and patient care, antifungal drug action and resistance and diagnostics.”

David combined the formation of GAFFI with his clinical and university duties from 2013-2020 and has now retired from clinical practice and leadership of the National Aspergillosis Centre. His current GAFFI work is focussed on enabling access and antifungal therapy in as many countries as possible and supporting higher quality care. He is also the coordinator of the LIFE (Leading International Fungal Education) program (www.LIFE-Worldwide.org), a global educational resource on fungal disease, on behalf of the Fungal Infection Trust[DD1]. His continuing University of Manchester role involves education and improving the understanding of the genetics of chronic pulmonary aspergillosis.

David has published more than 600 articles that have been cited more than 80,000 times and has an h-index of 121. He was the number one cited research author in Europe in Mycology (5th in Microbiology) in 2012 and was a Clarivate Analytics highly cited ISI highly cited researcher in 2019 and 2020.